Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Company Data

Name Kalaris Therapeutics, Inc. - Common Stock

Company Kalaris Therapeutics Inc

Symbol KLRS

Website https://kalaristx.com

Primary Exchange

NASDAQ

ISIN US4829291065

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Andrew Oxtoby

Market Capitalization 48 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 139 Main Street, Suite 500, 02142 Cambridge

IPO Date 2020-07-30

ID Changes

Date	From	To
19.03.2025	ALVR	KLRS

Ticker Symbols

Name	Symbol
NASDAQ	KLRS

More Shares

Investors who hold Kalaris Therapeutics, Inc. - Common Stock also have the following shares in their portfolio:

VATTENFALL AB SUB FLTG RST 7 YR CAP SECS 19/03/77 Bond

ZAPTEC AS NK -,00625 Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog